ArticleFolia microbiologica2025
Fibronectin recognition by the emerging multidrug-resistant opportunistic fungal pathogen Candida haemulonii.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The multidrug-resistant pathogen Candida haemulonii (Candidozyma haemuli) can cause superficial and systemic infections in vulnerable individuals. The ability of C. haemulonii to interact with extracellular matrix (ECM) components remains largely unexplored. Herein, we investigated C. haemulonii's capacity to bind to fibronectin and assessed how this ECM protein influences fungal adhesion and biofilm development. The results revealed that C. haemulonii yeasts can recognize and interact with soluble fibronectin in a dose-dependent and isolate-specific manner, as demonstrated by flow cytometry. Confocal microscopy confirmed that fibronectin-binding molecules are primarily localized at the periphery of the yeasts, indicating that the binding sites reside on the cell surface. Additionally, C. haemulonii exhibited significantly greater adhesion to polystyrene surface coated with immobilized fibronectin (48.8 ± 5.1 yeasts/microscopic field) compared to either uncoated (28.4 ± 6.5) or albumin-coated (28.7 ± 5.3) surfaces. Fungal biofilm formation was significantly reduced on fibronectin-coated surface in comparison to uncoated control, with both biomass and ECM production decreasing by about 50%, as evaluated by crystal violet and safranin staining, respectively. Western blot analysis revealed that C. haemulonii cells degraded fibronectin during biofilm development. Notably, cell-free biofilm supernatant was capable of cleaving soluble fibronectin; this degradation was partially inhibited by PMSF, indicating the involvement of serine proteases in this process. Corroborating this finding, zymography revealed two serine proteases (50 and 60 kDa) capable of degrading immobilized fibronectin. Collectively, the results demonstrate that C. haemulonii possesses fibronectin-binding molecules that contribute to adhesion and play a critical role in the early stages of its pathogenic process.
Indexed as
Identifiers
41258615What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.